Bavarian Nordic says that an interim analysis of two clinical trials of its experimental breast cancer vaccine shows that the therapy appears to be well tolerated and immunogenic. No adverse events have been reported to date.
The first study in the US is evaluating MVA-BN-HER2 treatment following chemotherapy and Herceptin treatment. In the second study, performed in Serbia and Poland, MVA-BN-HER2 is being evaluated following only chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors over-express HER2. Patients are vaccinated 3 times, at 3 week intervals, with the MVA-BN viral vector which has been engineered to express the extracellular fragment of human HER2.
"I am pleased that we once again can confirm the unique safety profile of MVA-BN and that we have been able to show immunogenicity in this patient group suffering from this severe disease," said Anders Hedegaard, the president and CEO of Bavarian Nordic.
- read the release for more